NCT04753762: IMACovid

Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection

Completed Last updated 8 May 2023

What this trial tests

trial in COVID-19 Virus Disease in 50 participants. Completed in 1 February 2022.

Timeline

1 March 2020

Primary endpoint
1 January 2021

1 February 2022

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 March 2020
Primary completion	1 January 2021
Estimated completion	1 February 2022
Sites	1 location across France

Conditions studied

• COVID-19 Virus Disease — all drugs for COVID-19 Virus Disease →
• Cardiac Complication — all drugs for Cardiac Complication →

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 18 to 79, any sex, with COVID-19 Virus Disease or Cardiac Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus Disease 2019 (COVID-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), which affects multiple organ system particularly the lung and heart. Indeed, SARS CoV-2 has various cardiac manifestations which are associated with higher mortality and morbidity. Cardiac involvement, based on elevated levels of myocardial enzymes, have been described in 20 to 30% of COVID-19 infection. However, the physiopathological mechanisms of myocardial injury remains unclear. Main hypothesis include inflammation and cytokine storm, hypercoagulability and vascular thrombosis, inflammation or stress leading to coronary plaque rupture (type I myocardial infarction), supply-demand mismatch and hypoxemia resulting in myocardial damage (type II myocardial infarction) ...

Two patterns can be identified : ischemic or non-ischemic pattern including myocarditis, stress induced cardiomyopathy, thrombo-embolic disease. However, the consequences of myocardial damage after confirmed COVID-19 infection are unknown at medium to long term prognosis.

Data are needed to identify myocardial damage and to guide effective therapies and follow-up (use of ACE inhibitor, beta-blockers, steroids...? ) In this study, the investigators proposed to collect multimodal cardiac imaging including MRI (Magnetic Resonance Imaging) and TTE (Transthoracic echocardiogram) in order to identify and characterize cardiac injury as ischemic or non-ischemic pattern, to better assess risk stratification and to guide effective therapies if necessary.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cardiac involvement in the long-term implications of COVID-19.
   Satterfield BA, Bhatt DL, Gersh BJ. · · 2022 · cited 101× · PMID 34686843 · DOI 10.1038/s41569-021-00631-3
2. Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave.
   Filippetti L, Pace N, Louis JS, Mandry D, et al · · 2022 · cited 13× · PMID 35355964 · DOI 10.3389/fcvm.2022.831580